(3-Azido-5-methyl-hex-1-ynyl)-triisopropyl-silane | 913619-06-4

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: (3-Azido-5-methyl-hex-1-ynyl)-triisopropyl-silane
• CAS: 913619-06-4
• 化学式: C₁₆H₃₁N₃Si
• 分子量: 293.528
• InChiKey: UTWCQXDTTOBEHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.93
• 重原子数：
  20.0
• 可旋转键数：
  6.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  48.76
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  (3-Azido-5-methyl-hex-1-ynyl)-triisopropyl-silane 、 5-甲基-1-己炔-3-醇 在 L-ascorbic acid sodium salt 、 copper(II) sulfate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 15.0h， 以71%的产率得到
  参考文献：
  名称：

  Synthesis of azide-alkyne fragments for ‘click’ chemical applications; formation of oligomers from orthogonally protected trialkylsilyl-propargyl azides and propargyl alcohols

  摘要：

  A series of orthogonally protected 1,4-disubstituted-1,2,3-triazoles were prepared from the corresponding alkynols and trialkylsilyl-propargyl azides via 1,3-dipolar cycloaddition. These cycloadducts were selectively deprotected and extended in a stepwise fashion via further 'click' reactions to form oligomeric peptidomimetic compounds. This methodology gives access to triazolebased peptidomimetics in a controlled fashion and lays the foundation for a fragment-based approach to drug discovery. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.07.131
• 作为产物：
  描述：

  5-Methyl-1-triisopropylsilanyl-hex-1-yn-3-ol 在 sodium azide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3-Azido-5-methyl-hex-1-ynyl)-triisopropyl-silane
  参考文献：
  名称：

  Synthesis of azide-alkyne fragments for ‘click’ chemical applications; formation of oligomers from orthogonally protected trialkylsilyl-propargyl azides and propargyl alcohols

  摘要：

  A series of orthogonally protected 1,4-disubstituted-1,2,3-triazoles were prepared from the corresponding alkynols and trialkylsilyl-propargyl azides via 1,3-dipolar cycloaddition. These cycloadducts were selectively deprotected and extended in a stepwise fashion via further 'click' reactions to form oligomeric peptidomimetic compounds. This methodology gives access to triazolebased peptidomimetics in a controlled fashion and lays the foundation for a fragment-based approach to drug discovery. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.07.131